📰 Context Therapeutic News
Context Therapeutic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Context Therapeutic. Real-time updates on events, politics, business and more.
August 10, 2023
Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactives Stephen Gunnion through progress with the companys lead program, CTIM-76. Lehr...
May 17, 2023
ASCO 2023 Spotlight: Claudin 6 Anticipated To Shine
March 29, 2023
Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Context Therapeutics in a research note issued on Thursday, March 23rd. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright […]
March 27, 2023
HC Wainwright downgraded shares of Context Therapeutics (NASDAQ:CNTX – Get Rating) from a buy rating to a neutral rating in a report issued on Thursday morning, The Fly reports. HC Wainwright also issued estimates for Context Therapeutics’ FY2027 earnings at ($0.30) EPS. Context Therapeutics Stock Performance Context Therapeutics stock opened at $0.62 on Thursday. The […]
March 27, 2023
HC Wainwright lowered shares of Context Therapeutics (NASDAQ:CNTX – Get Rating) from a buy rating to a neutral rating in a research note issued to investors on Thursday, The Fly reports. HC Wainwright also issued estimates for Context Therapeutics’ FY2027 earnings at ($0.30) EPS. Context Therapeutics Price Performance Shares of CNTX opened at $0.62 on […]
May 15, 2022
Analysts expect that Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) will post earnings per share of ($0.29) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Context Therapeutics’ earnings. The company is expected to announce its next earnings report on Monday, January 1st. According to Zacks, analysts expect that Context Therapeutics […]
April 13, 2022
Context Therapeutics’ (NASDAQ:CNTX – Get Rating) lock-up period will end on Monday, April 18th. Context Therapeutics had issued 5,000,000 shares in its public offering on October 20th. The total size of the offering was $25,000,000 based on an initial share price of $5.00. Shares of the company owned by company insiders and major shareholders will […]
December 2, 2021
02.12.2021 - PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) - Context Therapeutics Inc. (Nasdaq: CNTX) (Context Therapeutics or the Company), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and ... Seite 1